Caplin Point Laboratories Limited announced key decisions following its Board of Directors meeting held on August 12, 2026. The Board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and recommended a final dividend of ₹4 per equity share. Additionally, the re-appointments of Dr. Sridhar Ganesan as Managing Director and Mr. D. Muralidharan as Whole-Time Director were approved.
Board Meeting Outcomes
Caplin Point Laboratories Limited disclosed the outcomes of its Board of Directors meeting held on August 12, 2026. The Board has approved the unaudited standalone and consolidated financial results for the quarter and year ended June 30, 2026. A limited review report was also approved as part of this decision.
Dividend Recommendation
A significant financial decision was the recommendation of a final dividend of ₹4 (200%) per equity share of ₹2 each for the financial year ended March 31, 2026. This dividend, subject to shareholder approval at the upcoming Annual General Meeting (AGM), is slated to be paid on or before October 24, 2026. The Record Date for determining shareholder eligibility will be communicated separately.
Key Management Appointments
The Board also approved the re-appointment of Dr. Sridhar Ganesan (DIN: 06819026) as the Managing Director for a further period of two years, effective from August 25, 2026, to August 24, 2028. This re-appointment is subject to shareholder approval at the AGM.
Furthermore, the appointment of Mr. D. Muralidharan (DIN: 08301904) as a Whole-Time Director for a period of two years, effective from August 12, 2026, to August 11, 2028, was approved. Mr. Muralidharan will continue in his role as the Chief Financial Officer.
Annual General Meeting Details
The 35th Annual General Meeting (AGM) of the Company has been scheduled for Friday, September 25, 2026, and will be conducted through Video Conferencing / Other Audio-Visual means. The meeting commenced at 10:45 AM and concluded at 01:25 PM.
Financial Highlights (Unaudited Standalone – Q1 FY27 vs Q1 FY26)
- Revenue from operations increased to ₹202.95 Crores from ₹191.36 Crores.
- Other income decreased to ₹62.79 Crores from ₹72.39 Crores.
- Total Income rose to ₹265.74 Crores from ₹263.75 Crores.
- Total Expenses were ₹115.15 Crores, marginally up from ₹114.72 Crores.
- Profit Before Tax stood at ₹150.59 Crores, an increase from ₹149.03 Crores.
- Net Profit for the period was ₹120.38 Crores, compared to ₹120.81 Crores in the previous year.
- Basic Earnings Per Share (EPS) was ₹15.84, compared to ₹15.89 in the previous year.
Financial Highlights (Unaudited Consolidated – Q1 FY27 vs Q1 FY26)
- Revenue from Operations increased to ₹610.36 Crores from ₹510.22 Crores.
- Other Income increased to ₹33.55 Crores from ₹23.14 Crores.
- Total Revenue grew to ₹643.91 Crores from ₹533.36 Crores.
- Total Expenses were ₹418.68 Crores, up from ₹415.08 Crores.
- Profit Before Tax stood at ₹225.22 Crores, an increase from ₹184.46 Crores.
- Net Profit for the period was ₹179.09 Crores, compared to ₹150.76 Crores in the previous year.
- Basic Earnings Per Share (EPS) was ₹23.27, compared to ₹20.10 in the previous year.
Source: BSE
